News for Clinigen Group plc (CLIN.L)

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will...

The global real world evidence solutions market is driven by the rise in the incidence of cancer and chronic illnesses, a significant increase in the...

/PRNewswire/ -- The clinical trial supplies market size is expected to grow by USD 1.19 billion from 2022 to 2027. In addition, the momentum of the market will...

The global RWE oncology market is expected to approach US$ 1,715 million by 2030, with an annual growth rate of more than 13.2%, market report by...

Adlai Nortye filed for $72M IPO for its cancer drug development with a candidate in advanced stages of trials and solid financials. Learn more on ANL stock here.

Adlai Nortye Ltd. has filed to raise $115 million in a U.S. IPO, although the final figure may differ. Click for my first look at the ANL IPO and its prospects.

Real world evidence solutions market is segmented based on the component, application and end-user. Based on the component, the real world evidence...

Newark, New Castle, USA, July 05, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports have estimated that the global RWE oncology market was valued at...

Visiongain has published a new report entitled Clinical Trial Supplies 2023-2033. It includes profiles of Clinical Trial Supplies and Forecasts Market...

/PRNewswire/ -- The "U.S. Real-World Evidence Solutions Market by Component, Application, End User - Forecast to 2029" report has been added to...

Octopus AIM VCT plc Half-Yearly Results Octopus AIM VCT plc is a venture capital trust which aims to provide shareholders with attractive tax-free dividends and long-term capital growth by... | October 26, 2022

According to Fortune Business Insights, The Enzyme Replacement Therapy Market size is anticipated to reach USD 20.58 Billion in 2028, the market size was...

/PRNewswire/ -- The compounding pharmacies market value is expected to reach USD 18.2 billion by 2030, according to a new research report by Global Market...

Octopus AIM VCT 2 plc Half-Yearly Results Octopus AIM VCT 2 plc (the “Company”) is a venture capital trust (“VCT”) which aims to...

Octopus AIM VCT plc Final Results Octopus AIM VCT plc today announces the final results for the year ended 28 February 2022. Octopus AIM VCT plc...

Key Prominent Players Covered in the Enzyme Replacement Therapy Market are BioMarin (San Rafael, U.S.), Leadiant Biosciences, Inc. (Gaithersburg, U.S.),...

/PRNewswire/ -- According to Coherent Market Insights, The global compounding pharmacies market is estimated to account for 14,116.4 Mn in terms of value by...

Octopus AIM VCT 2 plc 18 August 2021 Portfolio Update The investment portfolio of Octopus AIM VCT 2 plc (the "Company") as at 18 August 2021 is as...